Ayala Pharma to merge with Advaxis Inc.,
Ayala Pharmaceuticals, Inc. a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers and Advaxis, Inc. a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes, announced that they have entered into a definitive merger agreement
The merger would result in a combined company that will focus predominantly on the development and commercialization of Ayala’s lead program AL 102 for the treatment of desmoid tumors and Advaxis’s candidate ADXS 504 in development for prostate cancer. At the closing of the merger, Ayala will be delisted from The Nasdaq Global Market.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
